Condition: Rheumatoid Arthritis · Pemphigus Vulgaris · Granulomatosis With Polyangiitis · Sponsor: IRIS Research and Development, LLC
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
This description comes directly from the study's public registry record.
Kathy I Perez, M.D. · 954-476-2338 · kperez@irisrheumatology.com
Jhon Galindo, B.S. · 9544762338 · jgalindo@irisrheumatology.com
Always discuss trial participation with your own doctor first.
| IRIS Research and Development, LLC | Plantation, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06581562